3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.
US-based central nervous system (CNS) disorder-focused drug developer Impel NeuroPharma floated on Friday in an $80m initial public offering representing an exit for manufacturing group 3M. The offering consisted of just over 5.3 million shares priced at $15.00 each, in the middle of the IPO’s $14 to $16 range, and they closed trading at the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.